Unnamed: 0,title,date,stock,sentiment
217790.0,Cellular Biomedicine Gr Q1 EPS $(0.600) Down From $(0.510) YoY,2020-05-06 16:50:00-04:00,CBMG,neutral
217791.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,CBMG,positive
217792.0,"Benzinga's Top Upgrades, Downgrades For March 5, 2020",2020-03-05 10:05:00-05:00,CBMG,positive
217793.0,BTIG Research Downgrades Cellular Biomedicine Gr to Neutral,2020-03-05 04:48:00-05:00,CBMG,neutral
217794.0,Cellular Biomedicine Says Received New Prelim. Non-Binding Proposal For $19.50/Share,2020-02-24 08:26:00-05:00,CBMG,neutral
217795.0,48 Biggest Movers From Yesterday,2020-01-08 04:45:00-05:00,CBMG,neutral
217796.0,34 Stocks Moving In Tuesday's Mid-Day Session,2020-01-07 12:10:00-05:00,CBMG,neutral
217797.0,Cellular Biomedicine Group Announces Engagement Of Independent Advisors By Special Committee Formed To Evaluate Strategic Alternatives Including $19.50/Share Preliminary Non-Binding Proposal,2019-12-30 08:31:00-05:00,CBMG,positive
217798.0,"Cellular Biomedicine Group Presents First Clinical Data of IIT Phase 1 Trial of C-CAR088, a Novel BCMA CAR-T at ASH 2019",2019-12-07 08:13:00-05:00,CBMG,positive
217799.0,"Benzinga's Top Upgrades, Downgrades For November 12, 2019",2019-11-12 09:37:00-05:00,CBMG,positive
217800.0,10 Biggest Price Target Changes For Tuesday,2019-11-12 08:14:00-05:00,CBMG,neutral
217801.0,"Baird Downgrades Cellular Biomedicine Gr to Neutral, Lowers Price Target to $19",2019-11-12 06:21:00-05:00,CBMG,negative
217802.0,"Cellular Biomedicine Shares Resume Trade, Up 4-5%",2019-11-11 10:30:00-05:00,CBMG,positive
217803.0,Cellular Biomedicine Shares To Resume Trade At 10:30 a.m. EST,2019-11-11 10:03:00-05:00,CBMG,positive
217804.0,"UPDATE: Cellular Biomedicine Offer From Consortium Led By CEO Tony Liu, Other Senior Mgmt. Members, Hillhouse Bio, TF Capital, Dangdai Int'l., Mission Right",2019-11-11 10:01:00-05:00,CBMG,neutral
217805.0,Cellular Biomedicine Group Reports Receipt Of Prelim. Non-Binding Go Private Offer At $19.50/Share In Cash,2019-11-11 10:01:00-05:00,CBMG,neutral
217806.0,"Cellular Biomedicine Group Shares Halted, News Pending",2019-11-11 09:59:00-05:00,CBMG,positive
217807.0,Cellular Biomedicine Gr Q3 EPS $(0.82) Misses $(0.67) Estimate,2019-11-06 17:23:00-05:00,CBMG,negative
217808.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,CBMG,positive
217809.0,"Benzinga's Top Upgrades, Downgrades For September 17, 2019",2019-09-17 10:38:00-04:00,CBMG,positive
217810.0,"BTIG Initiates Coverage On Cellular Biomedicine Gr with Buy Rating, Announces $19 Price Target",2019-09-17 08:12:00-04:00,CBMG,neutral
217811.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,CBMG,neutral
217812.0,Cellular Biomedicine Gr Q2 EPS $(0.63) Misses $(0.52) Estimate,2019-08-06 16:39:00-04:00,CBMG,negative
217813.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,CBMG,positive
217814.0,"Cantor Fitzgerald Initiates Coverage On Cellular Biomedicine Gr with Overweight Rating, Announces $27 Price Target",2019-06-25 06:50:00-04:00,CBMG,negative
217815.0,Cellular Biomedicine Group Announces First Patient Dosing in Phase I Clinical Trial of Anti-CD20 CAR-T for Lymphoma in China,2019-06-17 07:06:00-04:00,CBMG,neutral
217816.0,"Cellular Biomedicine Gr Q1 EPS $(0.51) Beats $(0.56) Estimate, Sales $49.265K Miss $50K Estimate",2019-04-30 18:18:00-04:00,CBMG,negative
217817.0,60 Biggest Movers From Yesterday,2019-03-22 05:36:00-04:00,CBMG,neutral
217818.0,48 Stocks Moving In Thursday's Mid-Day Session,2019-03-21 12:56:00-04:00,CBMG,neutral
217819.0,Cellular Biomedicine shares are trading lower after the company priced a 1.03 million share common stock offering at $17 per share.,2019-03-21 09:50:00-04:00,CBMG,positive
217820.0,Cellular Biomedicine Prices ~1.029M Share Offering At $17/Share,2019-03-21 09:03:00-04:00,CBMG,positive
217821.0,"The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering",2019-03-21 07:51:00-04:00,CBMG,negative
217822.0,"Cellular Biomedicine Group Reports Offering Of Common Stock, No Terms Disclosed",2019-03-20 16:02:00-04:00,CBMG,negative
217823.0,"Cellular Biomedicine Gr Laet Tuesday Reported Q4 EPS $(0.44) Beats $(0.50) Estimate, Sales $25.698K Miss $50K Estimate",2019-02-20 08:21:00-05:00,CBMG,negative
217824.0,"Benzinga's Top Upgrades, Downgrades For February 7, 2019",2019-02-07 09:05:00-05:00,CBMG,positive
217825.0,"Baird Initiates Coverage On Cellular Biomedicine Gr with Outperform Rating, Announces $26 Price Target",2019-02-07 06:52:00-05:00,CBMG,neutral
217826.0,Cellular Biomedicine Group's AlloJoin Therapy For Knee Osteoarthritis Becomes The First Stem Cell Drug Application Approved In China For Phase II Clinical Trials,2019-01-17 06:08:00-05:00,CBMG,positive
217827.0,Cellular Biomedicine Group Initiates Patient Recruitment for Clinical Trial in B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting Multiple Myeloma (MM),2019-01-09 03:57:00-05:00,CBMG,neutral
217828.0,"UPDATE: Cellular Biomedicine Says Novartis Seeks To Entrust Co.'s China Unit To Perform Certain Processing, Supply, Managerial Aspects Of Certain Products In China Region",2018-12-28 16:20:00-05:00,CBMG,positive
217829.0,"Cellular Biomedicine 8-K Shows Toll Manufacturing, Supply Deal With Beijing Novartis Pharma",2018-12-28 16:18:00-05:00,CBMG,neutral
217830.0,88 Biggest Movers From Yesterday,2018-11-08 04:54:00-05:00,CBMG,neutral
217831.0,"Cellular Biomedicine Gr Q3 EPS $(0.56) Misses $(0.52) Estimate, Sales $70.431K Beat $50K Estimate",2018-11-06 06:58:00-05:00,CBMG,negative
217832.0,44 Biggest Movers From Yesterday,2018-10-12 04:45:00-04:00,CBMG,neutral
217833.0,UPDATE: Cellular Biomedicine Group To Repurchase Shares Of Its Common Stock For A Purchase Price Not To Exceed $8.4M,2018-10-10 08:43:00-04:00,CBMG,positive
217834.0,"Cellular Biomedicine Group 8-K Shows On Oct. 10, Co. Commenced Buyback Program",2018-10-10 08:42:00-04:00,CBMG,neutral
217835.0,55 Biggest Movers From Yesterday,2018-10-04 05:29:00-04:00,CBMG,neutral
217836.0,43 Stocks Moving In Wednesday's Mid-Day Session,2018-10-03 13:09:00-04:00,CBMG,neutral
217837.0,Cellular Biomedicine Group Obtains NCI Patent License For Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology To Treat  Solid Tumors,2018-10-03 07:30:00-04:00,CBMG,positive
217838.0,46 Biggest Movers From Friday,2018-10-01 04:20:00-04:00,CBMG,neutral
217839.0,"Stocks Which Set New 52-Week High Yesterday, September 26th",2018-09-27 09:12:00-04:00,CBMG,neutral
217840.0,Cellular Biomedicine Shares To Resume Trade At 8 a.m. EDT,2018-09-27 07:56:00-04:00,CBMG,positive
217841.0,"Cellular Biomedicine Group Reports Strategic License, Collaboration Deal With Global Leader In CAR-T Cell Therapy For Patients In China",2018-09-27 07:31:00-04:00,CBMG,neutral
217842.0,Cellular Boimedicine Group Shares Halted News Pending,2018-09-27 07:27:00-04:00,CBMG,positive
217843.0,"Stocks Which Set New 52-Week High Yesterday, September 25th",2018-09-26 11:53:00-04:00,CBMG,neutral
217844.0,"The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial",2018-09-26 08:25:00-04:00,CBMG,positive
217845.0,"Cellular Biomedicine Gr Q2 EPS $(0.53) Down From $(0.43) YoY, Sales $77.313K Up From $62.914K YoY",2018-08-08 07:45:00-04:00,CBMG,neutral
217846.0,"Stocks Which Set New 52-Week High Yesterday, August 1st",2018-08-02 10:56:00-04:00,CBMG,neutral
217847.0,Maxim Group Terminates Cellular Biomedicine Gr Coverage,2018-06-15 16:30:00-04:00,CBMG,neutral
217848.0,"Cellular Biomedicine Reports Q1 EPS $(0.51), Sales $50.96M",2018-05-08 06:15:00-04:00,CBMG,neutral
217849.0,Cellular Biomedicine Group Announces 'Positive' 48-Week Clinical Data of AlloJoin Human Adipose-Derived Mesenchymal Progenitor Cell Knee Osteoarthritis China Phase I Trial,2018-03-16 07:08:00-04:00,CBMG,neutral
217850.0,Cellular Biomedicine Group S-3 Filing Shows Registration For ~2.93M Share Common Stock Offering Via Selling Holders,2018-03-05 17:39:00-05:00,CBMG,positive
217851.0,Sailing Capital Overseas Investments Fund Reports 10.1% Stake In Cellular Biomedicine,2018-02-14 13:17:00-05:00,CBMG,neutral
217852.0,8 Stocks Moving In Wednesday's After-Hours Session,2018-02-07 17:04:00-05:00,CBMG,neutral
217853.0,Cellular Biomedicine Group Announces $30.6M Investment from Sailing Capital Overseas Investment Ltd.,2018-02-05 08:19:00-05:00,CBMG,neutral
217854.0,46 Biggest Movers From Yesterday,2018-01-12 05:25:00-05:00,CBMG,neutral
217855.0,38 Stocks Moving In Thursday's Mid-Day Session,2018-01-11 13:18:00-05:00,CBMG,neutral
217856.0,48 Biggest Movers From Yesterday,2018-01-09 06:07:00-05:00,CBMG,neutral
217857.0,40 Biggest Movers From Friday,2018-01-08 05:59:00-05:00,CBMG,neutral
217858.0,30 Stocks Moving In Friday's Mid-Day Session,2018-01-05 12:15:00-05:00,CBMG,neutral
217859.0,31 Stocks Moving In Thursday's Mid-Day Session,2017-12-28 12:56:00-05:00,CBMG,neutral
217860.0,"Cellular Biomedicine Group Reports Q3 EPS $(0.43) vs $(0.48) Est., Sales $106.787M vs $10.012M YoY",2017-11-09 08:36:00-05:00,CBMG,neutral
217861.0,"Thermo Fisher Scientific, Cellular Biomedicine Group Reports Strategic Partnership to Develop Manufacturing Processes",2017-11-06 07:23:00-05:00,CBMG,neutral
217862.0,"Cellular Biomedicine Group Reports Q2 EPS $(0.43) vs $(0.52) In Sames Qtr. Last Year, Sales $62.914M vs $71.599M Est.",2017-08-08 17:02:00-04:00,CBMG,neutral
217863.0,Cellular Biomedicine Announce Xia Meng COO,2017-06-26 07:30:00-04:00,CBMG,neutral
217864.0,Cellular Biomedicine Reports $10M Buyback Plan,2017-06-01 06:05:00-04:00,CBMG,neutral
217865.0,Mid-Afternoon Market Update: Sorl Auto Parts Climbs After Strong Q1 Results; Westmoreland Shares Plunge,2017-05-15 14:44:00-04:00,CBMG,positive
217866.0,18 Biggest Mid-Day Gainers For Monday,2017-05-15 12:58:00-04:00,CBMG,neutral
217867.0,Mid-Day Market Update: Crude Oil Up 3%; Forterra Shares Drop After Q1 Results,2017-05-15 12:28:00-04:00,CBMG,negative
217868.0,Mid-Morning Market Update: Markets Open Higher; Thermo Fisher to Acquire Patheon For $35/Share,2017-05-15 10:01:00-04:00,CBMG,neutral
217869.0,Cellular Biomedicine Adds Second Clinical Site in Expansion of Chimeric Antigen Phase 1 Trial,2017-05-15 06:24:00-04:00,CBMG,neutral
217870.0,Cellular Biomedicine Group (CBMG) Announces the Addition of a Second Clinical Site in the Expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I Clinical Trial for Its CARD-1 Trial in Patients with Non-Hodgkin Lymphoma,2017-05-15 06:23:00-04:00,CBMG,neutral
217871.0,"Cellular Biomedicine Reports Q1 EPS $(0.43) vs $(0.35) Est., Sales $98.425M vs $488.491M YoY",2017-05-08 16:47:00-04:00,CBMG,neutral
217872.0,"Cellular Biomedicine Group Reports Deal with GE Healthcare Life Sciences China for Strategic Partnership to Establish Joint Technology Lab to Develop Control Processes for Manufacture of CAR-T, Stem Cell Therapies",2017-04-10 08:07:00-04:00,CBMG,neutral
217873.0,"Cellular Biomedicine FY EPS $(2.09) vs $(1.85) Est, Sales $628K vs $15M Est",2017-03-14 06:11:00-04:00,CBMG,neutral
217874.0,How The Ultra-Wealthy Are Helping Advance Health And Life Sciences,2017-03-10 15:58:00-05:00,CBMG,positive
217875.0,Money Is Energy: A Profile Of Family Office And Silk Legend Thomas Gütermann,2017-03-08 15:43:00-05:00,CBMG,positive
217876.0,"Exclusive: CBMG CEO Talks Stem-Cell Therapies, Cancer Treatments, Financials & The Chinese Market",2017-03-03 16:09:00-05:00,CBMG,negative
217877.0,Family Office Legend Thomas Gütermann Talks To The Media For The First Time Ever: 'We Opened A Fund Focused On Pre-IPO Unicorns',2017-03-03 12:10:00-05:00,CBMG,positive
217878.0,Cellular Biomedicine Group Awarded $2.29 Million Grant from the California Institute for Regenerative Medicine,2017-02-27 08:01:00-05:00,CBMG,positive
217879.0,Cellular Biomedicine Gets Approval for Commencement of CALL-1 Phase 1 Trial,2017-01-09 06:26:00-05:00,CBMG,positive
217880.0,Cellular Biomedicine Group To Commence Phase 1 Trial For C-CAR011 In China,2016-11-29 07:18:00-05:00,CBMG,neutral
217881.0,"Cellular Biomedicine Group Reports Q3 EPS $(0.75) vs. Prior Year Quarter $(0.44), Rev. $10K vs. Prior Year Quarter $624K",2016-11-08 16:48:00-05:00,CBMG,neutral
217882.0,Maxim Group Initiates Coverage on Cellular Biomedicine at Buy,2016-09-22 07:17:00-04:00,CBMG,neutral
217883.0,"Cellular Biomedicine Q2 EPS ($0.52), Revenue $71.6K, No Estimates",2016-08-09 06:54:00-04:00,CBMG,negative
217884.0,Dangdal International Group Reports 16.11% Stake in Cellular Biomedicine Group in 13D,2016-06-23 11:11:00-04:00,CBMG,neutral
217885.0,Cellular Biomedicine Group Reports Secondary Offering Of Up To 5.137M Shares Of Stock,2016-06-20 16:58:00-04:00,CBMG,positive
217886.0,"Cellular Biomedicine Reports Q1 Loss $4.3M, Sales $488.491K vs $1.8M Est.",2016-05-09 16:55:00-04:00,CBMG,negative
217887.0,Cellular Biomedicine Group Reports FY15 EPS $(1.70) vs. Prior Year Quarter $(1.43),2016-03-14 07:07:00-04:00,CBMG,neutral
217888.0,Cellular Biomedicine's Stock Surges After Company Receives Strategic Investment,2016-02-04 15:34:00-05:00,CBMG,neutral
217889.0,"Cellular Biomedicine Group Reports $43.13M Strategic Investment From Dangdai, 2.27M Shares At 19/Share; 10.4% Premium To Wed. Closing Price",2016-02-04 09:10:00-05:00,CBMG,positive
217890.0,Cellular Biomedicine Halted - News Dissemination,2016-02-04 09:10:00-05:00,CBMG,neutral
217891.0,Cellular Biomedicine Group Names Tony Liu as CEO,2016-01-28 06:07:00-05:00,CBMG,neutral
217892.0,Cellular Biomedicine Group Announces CEO Cap To Be Replaced By Liu,2016-01-11 09:03:00-05:00,CBMG,neutral
217893.0,Cellular Biomedicine Reports Launch of Phase 1 Trial for AlloJoin OTS Allogeneic Stem Cell Therapy,2016-01-06 09:06:00-05:00,CBMG,neutral
217894.0,Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis ReJoin® Stem Cell Therapy,2015-12-22 09:00:00-05:00,CBMG,neutral
217895.0,"Cellular Biomedicine Reports Q3 EPS $(0.44) Vs Est $(0.43), Sales $624.907K Vs Est $850K",2015-11-13 09:27:00-05:00,CBMG,neutral
217896.0,CBMG Responds to Inquiries From Investors and the Scientific Community About the Phase IIa Results From CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced B-cell Non-Hodgkin Lymphoma,2015-11-03 09:25:00-05:00,CBMG,positive
217897.0,Cellular Biomedicine Group to Present Phase IIa Results from CAR-T CD20 Immuno-Oncology Clinical Development Program for Advanced Diffuse Large B Cell Lymphoma,2015-10-23 08:16:00-04:00,CBMG,positive
217898.0,Cellular Biomedicine Spikes to High on Volume,2015-10-12 11:24:00-04:00,CBMG,neutral
217899.0,Cellular Biomedicine Group Reports Positive Results From CAR-T EGFR Immunotherapy in Advanced Relapsed/Refractory Patients With Solid Tumors,2015-09-28 08:57:00-04:00,CBMG,positive
217900.0,Cellular Biomedicine Group Responds to Inquiries From Investors and the Scientific Community About Its Immuno-Oncology Cell Therapy Platform,2015-09-28 07:35:00-04:00,CBMG,neutral
217901.0,Cellular Biomedicine Group to Present CAR-T Phase I Clinical Trial Data for Non Small Cell Lung Cancer and Other Solid Tumors at 5th World Congress on Cancer Therapy,2015-09-16 09:17:00-04:00,CBMG,negative
217902.0,Cellular Biomedicine Group to Release CAR-T for Non-Small Cell Lung Cancer Phase I Clinical Trial Data at 2015 European Cancer Congress,2015-09-14 09:27:00-04:00,CBMG,negative
217903.0,"Cellular Biomedicine Group Reports Q2 Loss $0.44 Vs Est Loss $0.37, Sales $656.959K Vs Est $650.0K",2015-08-14 07:01:00-04:00,CBMG,negative
217904.0,Cellular Biomedicine Names Dr. Yihong Yao Chief Scientific Officer,2015-08-11 08:35:00-04:00,CBMG,neutral
217905.0,"Cellular Biomedicine Group Announces Definitive Agreement To Purchase CD40LGVAX Vaccine, Related Technologies",2015-06-09 08:32:00-04:00,CBMG,positive
217906.0,Cellular Biomedicine Group Reports Publication of Human Adipose-Derived Progenitor Cells to Treat Knee Osteoarthritis,2015-06-05 08:31:00-04:00,CBMG,positive
217907.0,Cellular Biomedicine Group to Give Business and Clinical Updates at Jefferies 2015 Global Healthcare Conference,2015-05-29 09:02:00-04:00,CBMG,neutral
217908.0,Cellular Biomedicine Names Richard Wang as COO,2015-05-27 08:06:00-04:00,CBMG,neutral
217909.0,Benzinga's Volume Movers,2015-05-22 10:26:00-04:00,CBMG,neutral
217910.0,Cellular Biomedicine Group Reports Positive Phase I Results From CAR-T CD30 Immuno-Oncology Clinical Development Program,2015-05-22 09:17:00-04:00,CBMG,positive
217911.0,Cellular Biomedicine Q1 EPS -$0.39 vs -$0.40 est,2015-05-18 06:13:00-04:00,CBMG,neutral
217912.0,Cellular Biomedicine Group to Present Cancer CAR-T CD30 Therapy Clinical Development Program,2015-04-27 09:30:00-04:00,CBMG,negative
217913.0,Cellular Biomedicine Group Announces New Facility in Beijing,2015-04-22 09:39:00-04:00,CBMG,neutral
217914.0,Cellular Biomedicine Group Partners With Huntsworth Health to Build Global KOL Advocacy for Knee Osteoarthritis Stem Cell ReJoin(TM) Clinical Trials,2015-04-20 09:21:00-04:00,CBMG,neutral
217915.0,Cellular Biomedicine Group Moved to NASDAQ Global Market,2015-04-10 07:31:00-04:00,CBMG,neutral
217916.0,"Cellular Biomedicine Group Responds to False Statements, Allegations Made by Pump Stopper",2015-04-08 10:03:00-04:00,CBMG,neutral
217917.0,Citron Research @CitronResearch Tweet: $CBMG we warned you yesterday- report out today.  Stock to $5 pumpstopper.com/?p=345,2015-04-07 12:35:00-04:00,CBMG,negative
217918.0,"Pump Stopper Says Cellular Biomedicine Strong Sell On Patient Death, Fraud Ties And Stock Promotion, -94.6% Downside",2015-04-07 12:00:00-04:00,CBMG,negative
217919.0,Citron Research @CitronResearch $CBMG total joke of a bio stock.  If you are lucky enough to get a borrow- enjoy it...stock worth $5,2015-04-06 09:43:00-04:00,CBMG,positive
217920.0,"Cellular Biomedicine Reports FY14 EPS (1.43) vs. Est. $(1.53), Rev. $564K vs. Est. $400K",2015-03-31 08:49:00-04:00,CBMG,neutral
217921.0,Cellular Biomedicine Group Announces Interim Results From Phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin Therapy,2015-03-25 09:01:00-04:00,CBMG,neutral
217922.0,Morning Market Gainers,2015-02-09 09:48:00-05:00,CBMG,neutral
217923.0,"Cellular Biomedicine Group to Acquire Chinese PLA General Hospital's CAR-T Immuno-Oncology Technology, Clinical Data",2015-02-09 08:14:00-05:00,CBMG,neutral
217924.0,Cellular Biomedicine Group Initiates Patient Recruitment for Cartilage Damage Stem Cell Therapy Clinical Research Study,2015-01-06 08:02:00-05:00,CBMG,negative
217925.0,Cellular Biomedicine Group To Exercise Stock Options to Purchase Common Stock,2014-12-23 08:35:00-05:00,CBMG,neutral
217926.0,Cellular Biomedicine Group Releases Positive 48-Week Data From Phase I/IIa Clinical Trial For ReJoin,2014-12-05 11:01:00-05:00,CBMG,positive
217927.0,Cellular Biomedicine Group Launches Pre-Clinical Research Study for COPD,2014-10-16 08:29:00-04:00,CBMG,neutral
217928.0,Cellular Biomedicine Group Completes Acquisition of Agreen Biotech Co For $3.3M,2014-09-30 09:16:00-04:00,CBMG,neutral
217929.0,Events for the Week of Sept. 8-12,2014-09-10 14:34:00-04:00,CBMG,neutral
217930.0,Cellular Biomedicine Group Completes Twelve-Month Follow-Up of Patients From Phase I/IIa Clinical Trial for ReJoin(TM) Therapy for Knee Osteoarthritis ,2014-09-10 08:07:00-04:00,CBMG,neutral
217931.0,Morning Market Movers ,2014-09-02 09:46:00-04:00,CBMG,neutral
217932.0,Cellular Biomedicine launches Study On Human Adipose Mesenchymal Progenitor Cell ,2014-09-02 08:45:00-04:00,CBMG,neutral
217933.0,Cellular Biomedicine Says It Completed Treatment in Phase IIb Trail For Knee Osteoarthritis,2014-08-12 08:08:00-04:00,CBMG,neutral
217934.0,Cellular Biomedicine Group Announces Acquisition of Immune Cell Therapy Technology And U.S. Patent; $3.28M In Cash + 753K In CBMG Stock & 75K In CBMG Restricted Units,2014-08-04 09:19:00-04:00,CBMG,negative
217935.0,Shares of Cellular Biomedicine Quiet Ahead of Close Amid 13G Filing from Mission Right Ltd. Showing 8.2% Stake,2014-07-07 16:01:00-04:00,CBMG,positive
217936.0,"Cellular Biomedicine To Discontinue Consulting Business, Expects $840,000 Pretax Charge",2014-06-30 09:09:00-04:00,CBMG,neutral
217937.0,Cellular Biomedicine Group Discontinues Consulting Business Segment ,2014-06-30 09:07:00-04:00,CBMG,neutral
217938.0,Cellular Biomedicine Completes Phase IIB Enrollment,2014-06-26 08:15:00-04:00,CBMG,neutral
217939.0,Cellular Biomedicine Sold 1.49M Shares at $6.70/Share,2014-06-20 09:56:00-04:00,CBMG,positive
217940.0,Cellular Biomedicine Announces Positive Phase I/IIA Data Fro ReJoin,2014-06-19 08:32:00-04:00,CBMG,positive
217941.0,Cellular Biomedicine Group Completes Patient Treatment for Phase I Clinical Trial for Liver Cancer  ,2013-12-13 15:37:00-05:00,CBMG,negative
